Does Tranexamic acid fix all bleeding in surgery?

Authors

Taylor Lonjin, Dean Zhang, Praveen Prasanna

Published in

Journal of the National Medical Association. Jul 15, 2026. Epub Jul 15, 2026.

Abstract

Excessive hemorrhage is a major contributor to morbidity and mortality in perioperative settings. Tranexamic acid (TXA), a synthetic antifibrinolytic agent, effectively reduces blood loss by preventing fibrin degradation. This review summarizes the clinical applications, efficacy, and safety considerations of TXA across various surgical specialties. A comprehensive review of studies across various surgical specialties confirms TXA's efficacy in minimizing the risk of hemorrhage and transfusion needs. While TXA is a valuable tool in hemostasis, proper patient selection and dosing are crucial to avoid risks, especially in those with thromboembolic conditions or renal impairment. Further research is needed to refine dosing protocols and expand its safe use across patient populations.

PMID:
42632784
Bibliographic data and abstract were imported from PubMed on 23 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.